**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 45150

**Manuscript Type:** MINIREVIEWS

***Porphyromonas gingivalis* and digestive system cancers**

Zhou Y *et al.**Porphyromonas gingivalis* and cancers

Ying Zhou, Guang-Hua Luo

**Ying Zhou, Guang-Hua Luo**, Comprehensive Laboratory, the Third Affiliated Hospital of Soochow University, Changzhou 213003, Jiangsu Province, China

**ORCID number:** Ying Zhou (0000-0001-7359-8208); Guang-Hua Luo (0000-0001-8339-2828).

**Author contributions:** Zhou Y prepared the manuscript; Luo GH critically revised the intellectual content and gave final approval of manuscript.

**Supported by** Changzhou High-Level Medical Talents Training Project, No: 2016ZCLJ002.

**Conflict-of-interest statement:** The authors declare that there is no conflict of interest related to this study.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Invited manuscript

**Corresponding author: Guang Hua Luo, MD, PhD, Professor,** Comprehensive Laboratory, the Third Affiliated Hospital, Soochow University, No. 185, Juqian Street, Changzhou 213003, Jiangsu Province, China. shineroar@163.com

**Telephone:** +86-519-68870619

**Fax: +**86-591-86621235

**Received:** December 28, 2018

**Peer-review started:** December 29, 2018

**First decision:** January 30, 2019

**Revised:** February 26, 2019

**Accepted:** March 11, 2019

**Article in press:**

**Published online:**

**Abstract**

*Porphyromonas gingivalis* (*P. gingivalis*) is an anaerobic gram-negative bacterium that colonizes in the epithelium and has been strongly associated with periodontal disease. Recently, various degrees of associations between *P. gingivalis* and digestive system cancers, including oral squamous cell carcinoma in the oral cavity, oesophageal squamous carcinoma in the digestive tract, and pancreatic cancer in pancreatic tissues, have been displayed in multiple clinical and experimental studies. Since *P. gingivalis* has a strong association with periodontal diseases, not only the relationships between *P. gingivalis* and digestive system tumours but also the effects induced by periodontal diseases on cancers are well-illustrated in this review. In addition, the prevention and possible treatments for these digestive system tumours induced by *P. gingivalis* infection are also included in this review. At the end, we also highlighted the possible mechanisms of cancers caused by *P. gingivalis*. One important carcinogenic effect of *P. gingivalis* is inhibiting the apoptosis of epithelial cells, which also plays an intrinsic role in protecting cancerous cells. Some signalling pathways activated by *P. gingivalis* are involved in cell apoptosis, tumourigenesis, immune evasion and cell invasion of tumour cells. In addition, metabolism of potentially carcinogenic substances caused by *P. gingivalis* is also one of the connections between this bacterium and cancers.

**Key words:** *Porphyromonas gingivalis*; Oral squamous cell carcinoma; Oesophageal squamous cell carcinoma; Pancreatic cancer; Periodontal diseases

**© The Author(s) 2019.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** *Porphyromonas gingivalis* (*P. gingivalis*) has been discovered in many digestive system cancers, such as oral squamous cell carcinoma, oesophageal squamous cell carcinoma, and pancreatic cancer. For the strong association between *P. gingivalis* and periodontal diseases, we also interpret how periodontal diseases push effects on digestive system tumours. This review also presents some preventions and possible treatments for these cancers associated with *P. gingivalis* infection. In addition, the mechanisms by which *P. gingivalis* affects the occurrence and development of carcinomas are covered, including immune evasion, tumourigenesis, inhibition of apoptosis and invasion of tumour cells.

Zhou Y, Luo GH. *Porphyromonas gingivalis* and digestive system cancers. *World J Clin Cases* 2019; In press

**INTRODUCTION**

*Porphyromonas gingivalis* (*P. gingivalis*), one of several hundred bacterial species in the oral cavity, is an anaerobic gram-negative bacterium[[1](#_ENREF_1)] and is highly associated with periodontal diseases[2]. Dental plaque is a biofilm on the surface of teeth[3] and functions as a highly organized and integrated microbial community in the mouth[4]. *P. gingivalis* is part of the composition of dental plaque and endows dental plaque with a panoply of critical virulence attributes[5]. This bacterium regulates the immune reaction of host to promote the proliferation of microbial biofilm, thereby destroying the homeostasis of the host and causing biological disorders and disease[6]. *P. gingivalis* can be found in the gingival epithelium[7]. To effectively colonize, *P. gingivalis* secretes protein adhesins, hemin‐binding proteins and proteinases. Such factors could cause toxicity as well[8-10]. Arg-specific gingipains (RgpA and RgpB) and Lys-specific gingipain (Kgp) are cysteine proteinases, which are extracellular proteases with multiple effects on both the innate and adaptive immune responses[11,12]. These cysteine proteinases are capable of degrading extensive connective tissues and large host defence molecules[13,14]. The R-gingipains (Rgp) and Kgp are demonstrated highly related to the relief of inflammation and host defence evasion by means of activating kinin cascade and liquid phase transformation of complement C3 and C5 proteins[15,16]. Apart from these defences, some other factors, such as fimbriae, haemagglutinins, lipopolysaccharide, capsule polysaccharides, and major outer membrane protein, have also been demonstrated for potential virulence[17,18]. Recently, an increasing number of investigations have focused on cancers related to *P. gingivalis*. With the deepening of the research concerning this bacterium, outer membrane protein has been reported to make contributions to the interaction and colonization of host, the evasion of immune defense, as well as the destruction of periodontal tissues[19], which may explain how *P. gingivalis* pushes impacts on several digestive cancers. However, more and complicated internal mechanisms still need to be uncovered. This article aims to review the current relationship between *P. gingivalis* and cancer.

***P. GINGIVALIS* AND ORAL CANCER**

Oral cavity consists of diverse boundary surfaces, such as the gingiva, the back of the tongue, tongue side, oral mucosa and so on which contribute to the colonization and growth of various microorganisms. In 2016, accompanying an approximate 48330 new diagnoses and 9570 deaths, oral cancer was considered the sixth most common carcinoma globally[20]. Among these, what most commonly happened in oral cavity is oral squamous cell carcinoma (OSCC)[21]. *P. gingivalis* has been discovered colonizing in periodontium and spreading in the original lesion locations of OSCC as well, such as oral and lingual mucosa[22]. It is well known that tobacco and alcohol are the major risk factors for oral cancer, and approximately three-fourths of all oral and pharyngeal cancers are owing to tobacco smoking and alcohol drinking in the United States[23]. Upon alcohol drinking, *P. gingivalis* would dehydrogenate ethanol to acetaldehyde, which is a carcinogenic derivative and capable of contributing to DNA damage, mutation and excessive proliferation of the epithelium[24,25].

The concentration rate of *P. gingivalis* was discovered to be higher among cancer cells than normal tissues of the mouth by Katz *et al*[26] in 2011. Meanwhile, these authors suggested that *P. gingivalis* may lead to mouth cancer and the induction of epithelial cell transformation into a tumour. In a meta-analysis, the prevalence of *P. gingivalis* was 40.7%, and *P. gingivalis* made the chances of cancer and periodontal disease increasing 1.36 times[27]. Kang *et al*[28]’s study also showed that the incidence of *P. gingivalis* in patients with head and neck cancer and in healthy subjects is significantly different. Besides, compared to non-infected with *P. gingivalis* controls, those with long-term infection showed the up-regulating expressions of CD44 and CD133 which are the well-known cancer stem cell markers, and promoted the tumorigenic properties[29]. By activating ERK1/2-Ets1, p38/HSP27, and PAR2/NF-kB pathways, *P. gingivalis* increases pro-matrix metalloproteinase-9 (proMMP-9) levels and consequently promotes cellular invasion of OSCC cell lines when the proenzyme is stimulated by gingipains[30]. Comparing to uninfected cells, those infected with *P. gingivalis* cells were monitored to increase MMP-1, -2, -9 and -10 levels in time dependence[31]. In addition, activated MMP-9 has been illustrated to enhance the invasion of tumour cells; this study was performed with the help of a specific anti-MMP-9 blocking monoclonal antibody[32]. As Ha *et al*[33]’s findings also suggested, *P. gingivalis* infection makes significant functions in promoting the invasion of OSCC cells, including SCC-25, OSC-20 and SAS cells, through upregulating levels of IL-8 and MMPs (particularly MMP-1 and MMP-2). By establishing a long-term model in which human immortalized oral epithelial cells were chronically challenged with *P. gingivalis* for up to 23 weeks, Geng *et al*[34] found that long-term exposure to *P. gingivalis* accelerated the cell cycle and promoted cell migration as well as invasion abilities, both of which eventually induced metastatic proliferation in distant organs. Compared with non-infected *P. gingivalis* in mice, it was demonstrated that chronic infection would make the promotion of metastasis *via* the blood pathway *in vivo*[21].

***P. GINGIVALIS* AND OESOPHAGEAL CANCER**

On a global scale, oesophageal cancer, the eighth incidence of tumour also contributes to the sixth highest mortality. Asia, especially Central China, is a high-incidence area, whereas data recently revealed that newly-diagnosed cases are rising in Western Europe and America[35]. Oesophageal cancer is characteristic of difficulty in early diagnosis, rapid development and high mortality. Tobacco smoking and excess alcohol consumption are risk factors for oesophageal cancer[36]. This cancer has two major histological subtypes, squamous cell carcinoma and adenocarcinoma; the former is common in developing countries and the latter is more common in developed nations[37]. In this review, oesophageal squamous cell carcinoma (ESCC) is the focus. The similarity in histology between oesophageal squamous cells and oral squamous cells is well-known, and it has been revealed that there is a high frequency of *P. gingivalis* (61%) in ESCC[36]. In this study, the expression intensity of *P. gingivalis* antigen and the exclusive Lys-gingipain protease, as well as the detection of the *P. gingivalis*-specific 16S rDNA in ESCC patients, all of them were notably higher in tumour tissue than in ambient tissue or normal controls. In addition, the differentiation of tumour cells, the distant metastasis of ESCC, the survival ratio of ESCC patients and other clinicopathological factors all positively relate to the existence of *P. gingivalis*. Such conclusions not only firstly proved that infection with *P. gingivalis* would act as a new risk factor of ESCC, but also indicated that *P. gingivalis* could serve as a prognostic biomarker for ESCC[36]. The inhibition of epithelial cell apoptosis, the promotion of tumour cell immune invasion and the metabolism of potentially carcinogenic substances induced by *P. gingivalis* all contribute to the occurrence and development of ESCC[12,24,25,32,38,39]. Gao *et al*[40] firstly reported the implication between host immunologic reaction to P. gingivalis and malignant proliferation of ESCC cells. They also suggested that IgG and IgA for P. gingivalis played a role as possible serum markers of ESCC, and combining the both would advance the diagnosis and improve prognosis[40]. Finally, interestingly, the rate of infection of P. gingivalis is much higher in oesophageal cancers than in cardiac cancers and is approximately as low as zero in gastric cancer, which is due to lack of acid adaptation[41].

***P. GINGIVALIS* AND PANCREATIC CANCER**

Pancreatic cancer, which has a low frequency, is unexpectedly the fourth leading cause of death among various carcinomas, with an overall five-year survival rate of merely 8.2% (in 2007–2013) for all stages[42,43]. There are several factors leading to a poor prognostic performance of this devastating cancer, such as the deficiency of serum biomarkers for diagnosis and prognosis, the absence of biomarkers which could function as guidelines for individual therapy, and the broad and primary resistance to chemotherapy[43]. The bacterial colony is critical to developing gastrointestinal mucosal immune system, maintaining a normal physiological circumstance, and providing necessary nourishment, which has been of significance in various disease states[44,45]. Multiple observations have shown that there is an overlap between oral microbiota and digestive tract microbiota partly due to mastication and daily oral hygiene, such as tooth brushing and flossing[42], which promotes multiple avenues for the dissemination of dysbiosis[44]. Furthermore, poor oral health is linked with an increased risk of pancreatic cancer development[46]. Those who suffer from 2 types of periodontitis caused by oral microorganism tend to be subsequent at higher risks of increasing the occurrence of pancreatic cancer[47]. A large European prospective cohort study found that elevated serum antibodies to the ATTC 53978 strain of *P. gingivalis* could triple the risks of pancreatic carcinoma[48]. As Dr Miller recently demonstrated, *P. gingivalis* initiated the Toll-like receptor (TLR) signalling pathways[49], while TLR activation critically contributed to pancreatic carcinogenesis in animal models[50]. This result was considered direct evidence that *P. gingivalis* increases pancreatic cancer development. Additionally, high rates of tumour suppressor gene p53 mutations were detected in pancreatic cancer patients, and it was concluded that abnormality of the p53 gene is a significant event in human pancreatic tumourigenesis[51]. In addition, in the progression of *P. gingivalis* inhibiting epithelial cell apoptosis, p53 can be activated by *P. gingivalis* invasion[52,53]. As a result, mutations in p53 can play a role as a bridge that links *P. gingivalis* with the development of pancreatic cancer, but further investigations are needed to enrich this link.

In summary, *P. gingivalis* may be considered a biomarker in the occurrence and development of pancreatic cancer. It is urgent to conduct more research to explain the mechanism by which *P. gingivalis* acts on pancreatic cancer and to improve the prevention and treatment of pancreatic cancer. Through these studies, it is hopeful to contain the high mortality of pancreatic cancer and release the tense status quo in pancreatic cancer.

**PERIODONTAL DISEASE AND CANCERS**

Periodontal disease is an inflammation that occurs in gums, which could induce the recession of gum, the damage of soft tissue, and the loss of bone and tooth (severe periodontitis)[54]. The identification of the “red complex”, which consists of *Tannerella forsythia*, *P. gingivalis* and *Treponema denticola*, is a major milestone in the research of periodontal microbiology. In terms of esophageal adenocarcinoma risk, *Tannerella forsythia* has to be found increasing this risk, while the exhaustion of *Neisseria* and *Streptococcus pneumoniae* was related to lower risk, and the abundance of *P. gingivalis* tended to increase the risk of ESCC[55]. Among these bacterial species, *P. gingivalis* shows the strongest association with periodontitis[56]. Additionally, *P. gingivalis* acts as an independent risk factor for the above-mentioned cancers. Therefore, we further discuss the relationship between periodontitis and these cancers. Substantial investigations have accumulated evidence supporting that periodontitis causes the host maintain a chronic inflammatory state[57] and confirming that cancer is associated with chronic infections or inflammation[58]. Taking the receptor to advanced glycation end products (RAGE) as an example, which is a multi-ligand receptor that can express on numerous cytomembrane and link with chronic infections, has been suggested to play a role in carcinogenesis[59]. Consequently, we can conclude that periodontitis has direct effects on cancers. As a prospective cohort study revealed, periodontal disease might play the role of being a marker for a susceptible immune system or having a direct impact on cancer risk[60]. Some others also suggested that there are positive connections between periodontitis and several tumours, including pancreatic carcinoma, lung tumours and digestive cancers[61,62]. Tezal *et al*[63] concluded that chronic periodontal disease could function as a risk factor for oral premalignant lesions and cancers. OSCC patients are highly sensitive to chronic periodontitis, which suggests the existence of OSCC cells in a chronic inflammatory state. Since periodontitis is attributed to multiple bacterial pathogens, OSCC patients infected with such inflammation are in consistent exposure to excessive periodontal bacteria[64,65]. These bacterial pathogens may subsequently affect the biological behaviour of oral cancer by modulating inflammatory mediators and invading related molecules[31]. Chronic periodontitis not only affects the occurrence and development of oral cancer but also contributes to the metastasis of this cancer[29,31]. The relationship between periodontitis and pancreatic cancer has also been revealed from a great deal of research. An evidence-based review showed that inflammation plays a key role in pancreatic cancer[66], and in a prospective cohort study of male health, professionals confirmed the strong positive association between periodontal disease and pancreatic cancer. In this cohort study, the existence of periodontal disease increases the risk of pancreatic cancer by 64%[46]. The systemic dissemination of oral microorganism and their toxic substance may also cause systemic inflammation and immune reaction, which could trigger the incidence of pancreatic cancer[66-68]. However, the role of oral microbiota in the development of pancreatic cancer is still under study. As mentioned in a former section of this review, periodontal disease could induce the loss of a tooth[54]. A prospective study also suggested that tooth loss has increased the incidence of esophageal and gastric cancers, which may owe to the alterations of oral microflora and subsequent increased carcinogens *in vivo*[69,70]. As a result, periodontal disease is connected with such tumours. In addition, the risk of lung tumour has been increased for those who suffering from periodontal disease in cohort studies, which may be because of the aspiration of oral pathogens into the lungs, the modification of the mucosal surface, the destruction of salivary pellicles, and the alteration of the respiratory epithelium[71]. Periodontal disease may establish more connections with other cancers, such as bladder cancer, colorectal cancer and so on, but a large amount of research is needed to verify this connection.

**PREVENTION AND TREATMENT OF CANCERS ASSOCIATED WITH *P. GINGIVALIS* INFECTION**

The prevention and treatment to those digestive cancers are specific and complicated for the existence of *P. gingivalis*. As a result, the intervention strategies are separate to antimicrobial therapy[72] and tumour site[73], but which both devote to thoroughly extracting carcinomas and managing good prognosis.

For that *P. gingivalis* owns the characteristics of high genetic capability, this bacterium could resist any adverse environment that hindering its development; *P. gingivalis* could also be capable of resisting various antibiotics that in use currently. In addition, the results of Deshpande *et al*[74]’s study indicated that *P. gingivalis* can actively invade endothelial cells with the help of fimbriae. Because of the specificity of this bacterium, the cancer treatment related to *P. gingivalis* is more directional and targeted. First, screening for *P. gingivalis* in dental plaques may identify susceptible subjects, which could help decrease the occurrence of cancers. Second, we can improve oral hygiene to reduce the risk of cancer. Third, the use of antibiotics or other antibacterial strategies may prevent the progression of cancers[36]. Blue light-emitting diode (BL) could inhibit the growth of *P. gingivalis* and play antimicrobial roles, and antimicrobial photodynamic therapy combining BL and rose bengal was expected to be a new technology for the elimination of bacteria[72]. Besides, AM404, an active metabolite of paracetamol, is an inhibitor of the growth and biofilm formation of *P. gingivalis* and could potentially make guidance in developing new drugs that is specificto infections and cancers with regard to *P. gingivalis*[75]. There are data suggesting that Kgp, a factor that playing the role of nutrition and toxicity for *P. gingivalis*, may act as the therapeutic point in controlling *P. gingivalis* infections. On account of it relating to the inhibition of other bacterial pathogens, protease inhibitors may have a potential to be an emerging antibacterial drug[76]. However, when cancers occur, treatment decisions are often complicated. The location, staging and resectability of the primary tumour, individual factors, such as swallowing function and airway condition, wishing to keep organ preserved, and coexisting diseases, all play roles in guiding accurate therapy. The main therapeutic approaches towards cancers are surgical therapy and radiotherapy[73]. During the last decade, the introduction of intensity modulated radiation therapy and concomitant chemoradiation have substantially changed the treatment techniques in head and neck cancer[77] and solved problems caused by radiotherapy, such as rapidly progressing dental caries as well as fungal and bacterial infections[78,79]. Recently, the chronological order between dental extractions and radiotherapy has also been fully demonstrated[80]. As for oesophageal cancer, the avoidance of radiotherapy is a valid choice. And the combination of platinum-based chemotherapy and radiotherapy before operation is the first choice in treating resectable local oesophageal carcinoma. In addition, the use of cisplatin and 5-FU combined with chemo-radiotherapy is an effective strategy for the treatment of ESCC. Surgical retention is a salvage procedure for patients with persistent or recurrent diseases. Several multicentre trials regarding neoadjuvant treatment for pancreatic cancer to improve survival are in progress[81]. With regard to pancreatic cancer, considering its characteristic of diagnosis in advanced stages, surgery tends not to be a selection; radiotherapy or chemotherapy is mainly used for palliative care[54]. Neoadjuvant therapy has become increasingly important in recent years, and further changes in standards are still needed[82]. The improvements in surgery, the advance of radiotherapy and the coordinated use of systemic drugs during treatment have clinically contributed to better outcomes of cancer patients[73]. In summary, the combination of antimicrobial therapy against *P. gingivalis* and tumour clearance with surgery, radiotherapy or chemotherapy, and neoadjuvant therapy is a good treatment for these digestive system cancers caused by *P. gingivalis*. However, the prognosises of digestive cancers are not eventually same. As Woo *et al*[21] put, those OSCC patients who were infected with *P. gingivalis* are discovered more metastatic foci in the lung than those who were non-infected; ESCC patients those with high levels of IgA or IgG against *P. gingivalis* tend to worse prognosis and those who were detected with high both IgA and IgG were associated with worst prognosis[40]; Pancreatic cancer patients have suffered poor prognosis, partly for lacking diagnostic and prognostic biomarkers. It is better now for discovering the role of *P. gingivalis* in this devastating carcinoma, which would guide personalized treatments, improve prognosis and enhance the quality of life[43].

**POSSIBLE MECHANISMS OF CANCERS CAUSED BY *P. GINGIVALIS***

Regarding cancer, diverse degrees of connections between *P. gingivalis* and tumours of the buccal cavity, digestive tract or pancreas have been displayed in multiple clinical and experimental studies[26,48,62]. The correlation of orodigestive cancer mortality to *P. gingivalis* was first and directly illustrated in a cohort study from Ahn *et al*[62], who pinpointed that *P. gingivalis* would also act as a microbial marker full of value in such carcinomas. In this study, non-parametric trend analysis for all subjects also showed an increase in orodigestive cancer mortality with the increase of anti-*P. gingivalis* IgG levels[62]. *P. gingivalis* interacts with host epithelium in varieties of aspects, which may provide basis at molecular level for potential mechanisms carcinogenesis mediated by this bacterium. In addition to *P. gingivalis* inducing the invasion of tumour cells and activating TLR mentioned above[30,31,33,50], other possible mechanisms have also been identified. First, nucleoside diphosphate kinase (NDK) excreted by *P. gingivalis* is capable of promoting tumourigenesis. The NDK inhibits ATP activation of purinergic receptor (P2X7) receptors and consequently depress the production of IL-1β in epithelium[83]. In that IL-1β plays a crucial role in priming IFNγ which could produce CD8+ T cells that specific to tumour antigen, and NDK secreted by *P. gingivalis* can also make tumour escape from immune surveillance[39]. The degradation of ATP mediated by NDK also suppresses apoptosis, which is dependent on ATP activation of P2X7 receptors[84]. Moreover, the phosphorylation of heat shock protein 27 (HSP27) by NDK from *P. gingivalis* confers an antiapoptotic phenotype to primary gingival epithelial cells, suggesting that HSP27 is a critical molecule for the suppression of host cell apoptosis caused by *P. gingivalis*[85]. Second, Yilmaz *et al*[84] have noted that the inhibition of epithelial cell apoptosis is an important carcinogenic effect of *P. gingivalis* and is also an intrinsic protective mechanism of cancerous cells. Activating the Jak1/Akt/Stat3 signalling, increasing the Bcl2 (anti-apoptosis): Bax (pro-apoptosis) ratio, curtailing releasing pro-apoptotic factor cytochrome c, and blocking activating both caspase-9 and the executioner caspase-3 may all contribute to this progression[38,86,87]. In addition, *P. gingivalis* modulates the expressing levels of microRNAs (miRNAs), and the upregulation of miR-203 caused by *P. gingivalis* results in the decreasing levels of negative regulator SOCS3 and subsequently suppressing apoptosis of epithelium[88]. Since SOCS3 can bind to phosphorylated JAK receptors, SOCS3 consequently inhibits JAK/STAT3 signalling[89]. Third, *P. gingivalis* infection induces expression of the B7-H1 receptor which belongs to the B7 family and plays a significant regulatory role in immunologic reaction mediated by cells[90,91], suggesting that this pathogen is involved in transferring to the distant and advancing nuclear grading of carcinoma cells[92]. On the other hand, B7-H1 receptors-mediated costimulatory signal could cause the anergy and apoptotic effect of those activated T cells, which subsequently make tumours evade immune reaction[93]. Fourth, those carcinogenesis caused by *P. gingivalis* also contributes to metabolising potential carcinogen. For instance, *P. gingivalis* could dehydrogenate ethanol to acetaldehyde which is a carcinogenic derivative and capable of making the damage of DNA, the mutation and excessive proliferation of the epithelial cells[24,25]. Certainly, the above contributions could suitably explain why excessive drinking is a risk factor for orodigestive cancer[39]. Lastly, *P. gingivalis* establishes chronic infections that involve intracellular persistence within epithelial cells[[94](#_ENREF_94)]. Chronic inflammation has a close connection with the development of cancer for the release of inflammatory factors, such as IL-6, which can promote tumourigenesis by causing DNA hypomethylation as well as aberrant changes in promoter hypermethylation[95]. All the above-mentioned possible mechanisms of cancers caused by *P. gingivalis* are shown in Figure 1.

**CONCLUSION**

*P. gingivalis* is involved in periodontal disease and several cancers. This bacterium not only independently affects the development of cancers by RgpA, RgpB and Kgp[11,12] but also indirectly impacts cancers *via* periodontal disease that causes the host be in an inflammatory state[57,58]. One critical carcinogenesis caused by *P. gingivalis* is inhibiting the apoptotic effects of epithelium, which also function as the intrinsic protective mechanism of cancer cells[87]. *P. gingivalis* has a strong association with oral cancer, and the treatment of oral cancer is abundant and has been improved in the clinic. The significant function of *P. gingivalis* in oesophageal cancer was conducted by Gao *et al*[36] in 2017, which was considered a breakthrough in the research of oesophageal cancer and indicated that *P. gingivalis* can be an important biomarker for monitoring the occurrence and progression of this cancer. For pancreatic cancer, the evidence concerning the role of *P. gingivalis* is still limited, while the relationship between periodontal diseases and pancreatic cancer is very large[66-68]. Therefore, more investigations are still needed to reduce the incidence, increase the five-year survival rate and improve the treatments for this devastating cancer. Collectively, maintaining oral hygiene, seeking more biomarkers, improving therapeutic measures, and improving the prognosis of these diseases are the focus for clinical research and work in the future.

**REFERENCES**

1 **Haffajee AD**, Socransky SS. Microbial etiological agents of destructive periodontal diseases. *Periodontol 2000* 1994; **5**: 78-111 [PMID: 9673164 DOI: 10.1111/j.1600-0757.1994.tb00020.x]

2 **Dzink JL**, Socransky SS, Haffajee AD. The predominant cultivable microbiota of active and inactive lesions of destructive periodontal diseases. *J Clin Periodontol* 1988; **15**: 316-323 [PMID: 3292595 DOI: 10.1111/j.1600-051X.1988.tb01590.x]

3 **Marsh PD**. Dental plaque as a microbial biofilm. *Caries Res* 2004; **38**: 204-211 [PMID: 15153690 DOI: 10.1159/000077756]

4 **Struzycka I**. The oral microbiome in dental caries. *Pol J Microbiol* 2014; **63**: 127-135 [PMID: 25115106]

5 **Hajishengallis G**. Porphyromonas gingivalis-host interactions: open war or intelligent guerilla tactics? *Microbes Infect* 2009; **11**: 637-645 [PMID: 19348960 DOI: 10.1016/j.micinf.2009.03.009]

6 **Hajishengallis G**, Darveau RP, Curtis MA. The keystone-pathogen hypothesis. *Nat Rev Microbiol* 2012; **10**: 717-725 [PMID: 22941505 DOI: 10.1038/nrmicro2873]

7 **Colombo AV**, Silva CM, Haffajee A, Colombo AP. Identification of oral bacteria associated with crevicular epithelial cells from chronic periodontitis lesions. *J Med Microbiol* 2006; **55**: 609-615 [PMID: 16585650 DOI: 10.1099/jmm.0.46417-0]

8 **Travis J**, Pike R, Imamura T, Potempa J. Porphyromonas gingivalis proteinases as virulence factors in the development of periodontitis. *J Periodontal Res* 1997; **32**: 120-125 [PMID: 9085221 DOI: 10.1111/j.1600-0765.1997.tb01392.x]

9 **Lamont RJ**, Jenkinson HF. Life below the gum line: pathogenic mechanisms of Porphyromonas gingivalis. *Microbiol Mol Biol Rev* 1998; **62**: 1244-1263 [PMID: 9841671 DOI: 10.4161/viru.28930]

10 **Kuramitsu HK**. Proteases of Porphyromonas gingivalis: what don't they do? *Oral Microbiol Immunol* 1998; **13**: 263-270 [PMID: 9807117 DOI: 10.1111/j.1399-302X.1998.tb00706.x]

11 **Bostanci N**, Belibasakis GN. Porphyromonas gingivalis: an invasive and evasive opportunistic oral pathogen. *FEMS Microbiol Lett* 2012; **333**: 1-9 [PMID: 22530835 DOI: 10.1111/j.1574-6968.2012.02579.x]

12 **Popadiak K**, Potempa J, Riesbeck K, Blom AM. Biphasic effect of gingipains from Porphyromonas gingivalis on the human complement system. *J Immunol* 2007; **178**: 7242-7250 [PMID: 17513773 DOI: 10.4049/jimmunol.178.11.7242]

13 **Yamanaka A**, Kouchi T, Kasai K, Kato T, Ishihara K, Okuda K. Inhibitory effect of cranberry polyphenol on biofilm formation and cysteine proteases of Porphyromonas gingivalis. *J Periodontal Res* 2007; **42**: 589-592 [PMID: 17956474 DOI: 10.1111/j.1600-0765.2007.00982.x]

14 **Inomata M**, Ishihara Y, Matsuyama T, Imamura T, Maruyama I, Noguchi T, Matsushita K. Degradation of vascular endothelial thrombomodulin by arginine- and lysine-specific cysteine proteases from Porphyromonas gingivalis. *J Periodontol* 2009; **80**: 1511-1517 [PMID: 19722803 DOI: 10.1902/jop.2009.090114]

15 **Wingrove JA**, DiScipio RG, Chen Z, Potempa J, Travis J, Hugli TE. Activation of complement components C3 and C5 by a cysteine proteinase (gingipain-1) from Porphyromonas (Bacteroides) gingivalis. *J Biol Chem* 1992; **267**: 18902-18907 [PMID: 1527018 DOI: 10.1111/j.1432-1033.1992.tb17252.x]

16 **Discipio RG**, Daffern PJ, Kawahara M, Pike R, Travis J, Hugli TE, Potempa J. Cleavage of human complement component C5 by cysteine proteinases from Porphyromonas (Bacteroides) gingivalis. Prior oxidation of C5 augments proteinase digestion of C5. *Immunology* 1996; **87**: 660-667 [PMID: 8675224 DOI: 10.1046/j.1365-2567.1996.478594.x]

17 **Lamont RJ**, Jenkinson HF. Subgingival colonization by Porphyromonas gingivalis. *Oral Microbiol Immunol* 2000; **15**: 341-349 [PMID: 11154429 DOI: 10.1034/j.1399-302x.2000.150601.x]

18 **Holt SC**, Kesavalu L, Walker S, Genco CA. Virulence factors of Porphyromonas gingivalis. *Periodontol 2000* 1999; **20**: 168-238 [PMID: 10522227 DOI: 10.1111/j.1600-0757.1999.tb00162.x]

19 **Gui MJ**, Dashper SG, Slakeski N, Chen YY, Reynolds EC. Spheres of influence: Porphyromonas gingivalis outer membrane vesicles. *Mol Oral Microbiol* 2016; **31**: 365-378 [PMID: 26466922 DOI: 10.1111/omi.12134]

20 **Lee J**, Roberts JS, Atanasova KR, Chowdhury N, Han K, Yilmaz Ö. Human Primary Epithelial Cells Acquire an Epithelial-Mesenchymal-Transition Phenotype during Long-Term Infection by the Oral Opportunistic Pathogen, *Porphyromonas gingivalis*. *Front Cell Infect Microbiol* 2017; **7**: 493 [PMID: 29250491 DOI: 10.3389/fcimb.2017.00493]

21 **Woo BH**, Kim DJ, Choi JI, Kim SJ, Park BS, Song JM, Lee JH, Park HR. Oral cancer cells sustainedly infected with Porphyromonas gingivalis exhibit resistance to Taxol and have higher metastatic potential. *Oncotarget* 2017; **8**: 46981-46992 [PMID: 28388583 DOI: 10.18632/oncotarget.16550]

22 **Atanasova KR**, Yilmaz Ö. Prelude to oral microbes and chronic diseases: past, present and future. *Microbes Infect* 2015; **17**: 473-483 [PMID: 25813714 DOI: 10.1016/j.micinf.2015.03.007]

23 **Blot WJ**, McLaughlin JK, Winn DM, Austin DF, Greenberg RS, Preston-Martin S, Bernstein L, Schoenberg JB, Stemhagen A, Fraumeni JF Jr. Smoking and drinking in relation to oral and pharyngeal cancer. *Cancer Res* 1988; **48**: 3282-3287 [PMID: 3365707]

24 **Salaspuro MP**. Acetaldehyde, microbes, and cancer of the digestive tract. *Crit Rev Clin Lab Sci* 2003; **40**: 183-208 [PMID: 12755455 DOI: 10.1080/713609333]

25 **Homann N**, Jousimies-Somer H, Jokelainen K, Heine R, Salaspuro M. High acetaldehyde levels in saliva after ethanol consumption: methodological aspects and pathogenetic implications. *Carcinogenesis* 1997; **18**: 1739-1743 [PMID: 9328169 DOI: 10.1093/carcin/18.9.1739]

26 **Katz J**, Onate MD, Pauley KM, Bhattacharyya I, Cha S. Presence of Porphyromonas gingivalis in gingival squamous cell carcinoma. *Int J Oral Sci* 2011; **3**: 209-215 [PMID: 22010579 DOI: 10.4248/IJOS11075]

27 **Sayehmiri F**, Sayehmiri K, Asadollahi K, Soroush S, Bogdanovic L, Jalilian FA, Emaneini M, Taherikalani M. The prevalence rate of Porphyromonas gingivalis and its association with cancer: A systematic review and meta-analysis. *Int J Immunopathol Pharmacol* 2015; **28**: 160-167 [PMID: 26002887 DOI: 10.1177/0394632015586144]

28 **Kang MS**, Oh JS, Kim HJ, Kim HN, Lee IK, Choi HR, Kim OJ, Ko YJ, Lim WB, Park HJ, Yu MG, Yi CK. Prevalence of Oral Microbes in the Saliva of Oncological Patients. *J Bacteriol Virol* 2009; **39**: 277 [DOI: 10.4167/jbv.2009.39.4.277]

29 **Ha NH**, Woo BH, Kim DJ, Ha ES, Choi JI, Kim SJ, Park BS, Lee JH, Park HR. Prolonged and repetitive exposure to Porphyromonas gingivalis increases aggressiveness of oral cancer cells by promoting acquisition of cancer stem cell properties. *Tumour Biol* 2015; **36**: 9947-9960 [PMID: 26178482 DOI: 10.1007/s13277-015-3764-9]

30 **Inaba H**, Sugita H, Kuboniwa M, Iwai S, Hamada M, Noda T, Morisaki I, Lamont RJ, Amano A. Porphyromonas gingivalis promotes invasion of oral squamous cell carcinoma through induction of proMMP9 and its activation. *Cell Microbiol* 2014; **16**: 131-145 [PMID: 23991831 DOI: 10.1111/cmi.12211]

31 **Cho BH**, Jung YH, Kim DJ, Woo BH, Jung JE, Lee JH, Choi YW, Park HR. Acetylshikonin suppresses invasion of Porphyromonas gingivalis‑infected YD10B oral cancer cells by modulating the interleukin-8/matrix metalloproteinase axis. *Mol Med Rep* 2018; **17**: 2327-2334 [PMID: 29207110 DOI: 10.3892/mmr.2017.8151]

32 **Ramos-DeSimone N**, Hahn-Dantona E, Sipley J, Nagase H, French DL, Quigley JP. Activation of matrix metalloproteinase-9 (MMP-9) via a converging plasmin/stromelysin-1 cascade enhances tumor cell invasion. *J Biol Chem* 1999; **274**: 13066-13076 [PMID: 10224058 DOI: 10.1074/jbc.274.19.13066]

33 **Ha NH**, Park DG, Woo BH, Kim DJ, Choi JI, Park BS, Kim YD, Lee JH, Park HR. Porphyromonas gingivalis increases the invasiveness of oral cancer cells by upregulating IL-8 and MMPs. *Cytokine* 2016; **86**: 64-72 [PMID: 27468958 DOI: 10.1016/j.cyto.2016.07.013]

34 **Geng F**, Liu J, Guo Y, Li C, Wang H, Wang H, Zhao H, Pan Y. Persistent Exposure to *Porphyromonas gingivalis* Promotes Proliferative and Invasion Capabilities, and Tumorigenic Properties of Human Immortalized Oral Epithelial Cells. *Front Cell Infect Microbiol* 2017; **7**: 57 [PMID: 28286742 DOI: 10.3389/fcimb.2017.00057]

35 **Crew KD**, Neugut AI. Epidemiology of upper gastrointestinal malignancies. *Semin Oncol* 2004; **31**: 450-464 [PMID: 15297938 DOI: 10.1053/j.seminoncol.2004.04.021]

36 **Gao S**, Li S, Ma Z, Liang S, Shan T, Zhang M, Zhu X, Zhang P, Liu G, Zhou F, Yuan X, Jia R, Potempa J, Scott DA, Lamont RJ, Wang H, Feng X. Presence of Porphyromonas gingivalis in esophagus and its association with the clinicopathological characteristics and survival in patients with esophageal cancer. *Infect Agent Cancer* 2016; **11**: 3 [PMID: 26788120 DOI: 10.1186/s13027-016-0049-x]

37 **Hongo M**, Nagasaki Y, Shoji T. Epidemiology of esophageal cancer: Orient to Occident. Effects of chronology, geography and ethnicity. *J Gastroenterol Hepatol* 2009; **24**: 729-735 [PMID: 19646015 DOI: 10.1111/j.1440-1746.2009.05824.x]

38 **Mao S**, Park Y, Hasegawa Y, Tribble GD, James CE, Handfield M, Stavropoulos MF, Yilmaz O, Lamont RJ. Intrinsic apoptotic pathways of gingival epithelial cells modulated by Porphyromonas gingivalis. *Cell Microbiol* 2007; **9**: 1997-2007 [PMID: 17419719 DOI: 10.1111/j.1462-5822.2007.00931.x]

39 **Whitmore SE**, Lamont RJ. Oral bacteria and cancer. *PLoS Pathog* 2014; **10**: e1003933 [PMID: 24676390 DOI: 10.1371/journal.ppat.1003933]

40 **Gao SG**, Yang JQ, Ma ZK, Yuan X, Zhao C, Wang GC, Wei H, Feng XS, Qi YJ. Preoperative serum immunoglobulin G and A antibodies to Porphyromonas gingivalis are potential serum biomarkers for the diagnosis and prognosis of esophageal squamous cell carcinoma. *BMC Cancer* 2018; **18**: 17 [PMID: 29298684 DOI: 10.1186/s12885-017-3905-1]

41 **Yuan X**, Liu Y, Kong J, Gu B, Qi Y, Wang X, Sun M, Chen P, Sun W, Wang H, Zhou F, Gao S. Different frequencies of Porphyromonas gingivalis infection in cancers of the upper digestive tract. *Cancer Lett* 2017; **404**: 1-7 [PMID: 28705771 DOI: 10.1016/j.canlet.2017.07.003]

42 **Fan X**, Alekseyenko AV, Wu J, Peters BA, Jacobs EJ, Gapstur SM, Purdue MP, Abnet CC, Stolzenberg-Solomon R, Miller G, Ravel J, Hayes RB, Ahn J. Human oral microbiome and prospective risk for pancreatic cancer: a population-based nested case-control study. *Gut* 2018; **67**: 120-127 [PMID: 27742762 DOI: 10.1136/gutjnl-2016-312580]

43 **Amrutkar M**, Gladhaug IP. Pancreatic Cancer Chemoresistance to Gemcitabine. *Cancers* (Basel) 2017; **9**: pii: E157 [PMID: 29144412 DOI: 10.3390/cancers9110157]

44 **Pei Z**, Bini EJ, Yang L, Zhou M, Francois F, Blaser MJ. Bacterial biota in the human distal esophagus. *Proc Natl Acad Sci USA* 2004; **101**: 4250-4255 [PMID: 15016918 DOI: 10.1073/pnas.0306398101]

45 **Öğrendik M**. Oral bacteria in pancreatic cancer: mutagenesis of the p53 tumour suppressor gene. *Int J Clin Exp Pathol* 2015; **8**: 11835-11836 [PMID: 26617937]

46 **Michaud DS**, Joshipura K, Giovannucci E, Fuchs CS. A prospective study of periodontal disease and pancreatic cancer in US male health professionals. *J Natl Cancer Inst* 2007; **99**: 171-175 [PMID: 17228001 DOI: 10.1093/jnci/djk021]

47 **Jacob JA**. Study Links Periodontal Disease Bacteria to Pancreatic Cancer Risk. *JAMA* 2016; **315**: 2653-2654 [PMID: 27244554 DOI: 10.1001/jama.2016.6295]

48 **Michaud DS**, Izard J, Wilhelm-Benartzi CS, You DH, Grote VA, Tjønneland A, Dahm CC, Overvad K, Jenab M, Fedirko V, Boutron-Ruault MC, Clavel-Chapelon F, Racine A, Kaaks R, Boeing H, Foerster J, Trichopoulou A, Lagiou P, Trichopoulos D, Sacerdote C, Sieri S, Palli D, Tumino R, Panico S, Siersema PD, Peeters PH, Lund E, Barricarte A, Huerta JM, Molina-Montes E, Dorronsoro M, Quirós JR, Duell EJ, Ye W, Sund M, Lindkvist B, Johansen D, Khaw KT, Wareham N, Travis RC, Vineis P, Bueno-de-Mesquita HB, Riboli E. Plasma antibodies to oral bacteria and risk of pancreatic cancer in a large European prospective cohort study. *Gut* 2013; **62**: 1764-1770 [PMID: 22990306 DOI: 10.1136/gutjnl-2012-303006]

49 **Shaik-Dasthagirisaheb YB**, Huang N, Weinberg EO, Shen SS, Genco CA, Gibson FC 3rd. Aging and contribution of MyD88 and TRIF to expression of TLR pathway-associated genes following stimulation with Porphyromonas gingivalis. *J Periodontal Res* 2015; **50**: 89-102 [PMID: 24862405 DOI: 10.1111/jre.12185]

50 **Zambirinis CP**, Levie E, Nguy S, Avanzi A, Barilla R, Xu Y, Seifert L, Daley D, Greco SH, Deutsch M, Jonnadula S, Torres-Hernandez A, Tippens D, Pushalkar S, Eisenthal A, Saxena D, Ahn J, Hajdu C, Engle DD, Tuveson D, Miller G. TLR9 ligation in pancreatic stellate cells promotes tumorigenesis. *J Exp Med* 2015; **212**: 2077-2094 [PMID: 26481685 DOI: 10.1084/jem.20142162]

51 **Barton CM**, Staddon SL, Hughes CM, Hall PA, O'Sullivan C, Klöppel G, Theis B, Russell RC, Neoptolemos J, Williamson RC. Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer. *Br J Cancer* 1991; **64**: 1076-1082 [PMID: 1764370 DOI: 10.1038/bjc.1991.467]

52 **Yu Y**, Richardson DR. Cellular iron depletion stimulates the JNK and p38 MAPK signaling transduction pathways, dissociation of ASK1-thioredoxin, and activation of ASK1. *J Biol Chem* 2011; **286**: 15413-15427 [PMID: 21378396 DOI: 10.1074/jbc.M111.225946]

53 **Inaba H**, Amano A, Lamont RJ, Murakami Y, Matsumoto-Nakano M. Cell Cycle Arrest and Apoptosis Induced by Porphyromonas gingivalis Require Jun N-Terminal Protein Kinase- and p53-Mediated p38 Activation in Human Trophoblasts. *Infect Immun* 2018; **86**: pii: e00923-17 [PMID: 29339463 DOI: 10.1128/IAI.00923-17]

54 **Michaud DS**. Role of bacterial infections in pancreatic cancer. *Carcinogenesis* 2013; **34**: 2193-2197 [PMID: 23843038 DOI: 10.1093/carcin/bgt249]

55 **Peters BA**, Wu J, Pei Z, Yang L, Purdue MP, Freedman ND, Jacobs EJ, Gapstur SM, Hayes RB, Ahn J. Oral Microbiome Composition Reflects Prospective Risk for Esophageal Cancers. *Cancer Res* 2017; **77**: 6777-6787 [PMID: 29196415 DOI: 10.1158/0008-5472.CAN-17-1296]

56 **Socransky SS**, Haffajee AD, Cugini MA, Smith C, Kent RL Jr. Microbial complexes in subgingival plaque. *J Clin Periodontol* 1998; **25**: 134-144 [PMID: 9495612 DOI: 10.1111/j.1600-051X.1998.tb02419.x]

57 **Loesche WJ**, Grossman NS. Periodontal disease as a specific, albeit chronic, infection: diagnosis and treatment. *Clin Microbiol Rev* 2001; **14**: 727-752, table of contents [PMID: 11585783 DOI: 10.1128/CMR.14.4.727-752.2001]

58 **Mantovani A**, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. *Nature* 2008; **454**: 436-444 [PMID: 18650914 DOI: 10.1038/nature07205]

59 **Katz J**, Wallet S, Cha S. Periodontal disease and the oral-systemic connection: "is it all the RAGE?". *Quintessence Int* 2010; **41**: 229-237 [PMID: 20213024 DOI: 10.1016/j.jhsa.2014.06.068]

60 **Michaud DS**, Liu Y, Meyer M, Giovannucci E, Joshipura K. Periodontal disease, tooth loss, and cancer risk in male health professionals: a prospective cohort study. *Lancet Oncol* 2008; **9**: 550-558 [PMID: 18462995 DOI: 10.1016/S1470-2045(08)70106-2]

61 **Hujoel PP**, Drangsholt M, Spiekerman C, Weiss NS. An exploration of the periodontitis-cancer association. *Ann Epidemiol* 2003; **13**: 312-316 [PMID: 12821269 DOI: 10.1016/S1047-2797(02)00425-8]

62 **Ahn J**, Segers S, Hayes RB. Periodontal disease, Porphyromonas gingivalis serum antibody levels and orodigestive cancer mortality. *Carcinogenesis* 2012; **33**: 1055-1058 [PMID: 22367402 DOI: 10.1093/carcin/bgs112]

63 **Tezal M**, Sullivan MA, Hyland A, Marshall JR, Stoler D, Reid ME, Loree TR, Rigual NR, Merzianu M, Hauck L, Lillis C, Wactawski-Wende J, Scannapieco FA. Chronic periodontitis and the incidence of head and neck squamous cell carcinoma. *Cancer Epidemiol Biomarkers Prev* 2009; **18**: 2406-2412 [PMID: 19745222 DOI: 10.1158/1055-9965.EPI-09-0334]

64 **Wolff L**, Dahlén G, Aeppli D. Bacteria as Risk Markers for Periodontitis. *J Periodontol* 1994; **65** Suppl 5S: 498-510 [PMID: 29539763 DOI: 10.1902/jop.1994.65.5s.498]

65 **Abiko Y**, Sato T, Mayanagi G, Takahashi N. Profiling of subgingival plaque biofilm microflora from periodontally healthy subjects and from subjects with periodontitis using quantitative real-time PCR. *J Periodontal Res* 2010; **45**: 389-395 [PMID: 20337892 DOI: 10.1111/j.1600-0765.2009.01250.x]

66 **Greer JB**, Whitcomb DC. Inflammation and pancreatic cancer: an evidence-based review. *Curr Opin Pharmacol* 2009; **9**: 411-418 [PMID: 19589727 DOI: 10.1016/j.coph.2009.06.011]

67 **Joshipura KJ**, Wand HC, Merchant AT, Rimm EB. Periodontal disease and biomarkers related to cardiovascular disease. *J Dent Res* 2004; **83**: 151-155 [PMID: 14742654 DOI: 10.1177/154405910408300213]

68 **Meurman JH**. Oral microbiota and cancer. *J Oral Microbiol* 2010 [PMID: 21523227 DOI: 10.3402/jom.v2i0.5195]

69 **Abnet CC**, Qiao YL, Mark SD, Dong ZW, Taylor PR, Dawsey SM. Prospective study of tooth loss and incident esophageal and gastric cancers in China. *Cancer Causes Control* 2001; **12**: 847-854 [PMID: 11714113 DOI: 10.1023/a:1012290009545]

70 **Yin XH**, Wang YD, Luo H, Zhao K, Huang GL, Luo SY, Peng JX, Song JK. Association between Tooth Loss and Gastric Cancer: A Meta-Analysis of Observational Studies. *PLoS One* 2016; **11**: e0149653 [PMID: 26934048 DOI: 10.1371/journal.pone.0149653]

71 **Petersen PE**, Ogawa H. The global burden of periodontal disease: towards integration with chronic disease prevention and control. *Periodontol 2000* 2012; **60**: 15-39 [PMID: 22909104 DOI: 10.1111/j.1600-0757.2011.00425.x]

72 **Chui C**, Aoki A, Takeuchi Y, Sasaki Y, Hiratsuka K, Abiko Y, Izumi Y. Antimicrobial effect of photodynamic therapy using high-power blue light-emitting diode and red-dye agent on Porphyromonas gingivalis. *J Periodontal Res* 2013; **48**: 696-705 [PMID: 23441868 DOI: 10.1111/jre.12055]

73 **Argiris A**, Karamouzis MV, Raben D, Ferris RL. Head and neck cancer. *Lancet* 2008; **371**: 1695-1709 [PMID: 18486742 DOI: 10.1016/S0140-6736(08)60728-X]

74 **Deshpande RG**, Khan MB, Genco CA. Invasion of aortic and heart endothelial cells by Porphyromonas gingivalis. *Infect Immun* 1998; **66**: 5337-5343 [PMID: 9784541 DOI: 10.1007/BF02770849]

75 **Gerits E**, Spincemaille P, De Cremer K, De Brucker K, Beullens S, Thevissen K, Cammue BPA, Vandamme K, Fauvart M, Verstraeten N, Michiels J. Repurposing AM404 for the treatment of oral infections by Porphyromonas gingivalis. *Clin Exp Dent Res* 2017; **3**: 69-76 [PMID: 29744181 DOI: 10.1002/cre2.65]

76 **Curtis MA**, Aduse Opoku J, Rangarajan M, Gallagher A, Sterne JA, Reid CR, Evans HE, Samuelsson B. Attenuation of the virulence of Porphyromonas gingivalis by using a specific synthetic Kgp protease inhibitor. *Infect Immun* 2002; **70**: 6968-6975 [PMID: 12438376 DOI: 10.1128/IAI.70.12.6968-6975.2002]

77 **Bortfeld T**. IMRT: a review and preview. *Phys Med Biol* 2006; **51**: R363-R379 [PMID: 16790913 DOI: 10.1088/0031-9155/51/13/R21]

78 **Burlage FR**, Coppes RP, Meertens H, Stokman MA, Vissink A. Parotid and submandibular/sublingual salivary flow during high dose radiotherapy. *Radiother Oncol* 2001; **61**: 271-274 [PMID: 11730996 DOI: 10.1016/S0167-8140(01)00427-3]

79 **Epstein JB**, Lunn R, Le N, Stevenson-Moore P. Periodontal attachment loss in patients after head and neck radiation therapy. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 1998; **86**: 673-677 [PMID: 9868723 DOI: 10.1016/S1079-2104(98)90202-5]

80 **Koga DH**, Salvajoli JV, Alves FA. Dental extractions and radiotherapy in head and neck oncology: review of the literature. *Oral Dis* 2008; **14**: 40-44 [PMID: 18173447 DOI: 10.1111/j.1601-0825.2006.01351.x]

81 **Chiappa A**, Andreoni B, Dionigi R, Spaggiari L, Foschi D, Polvani G, Orecchia R, Fazio N, Pravettoni G, Cossu ML, Galetta D, Venturino M, Ferrari C, Macone L, Crosta C, Bonanni B, Biffi R. A rationale multidisciplinary approach for treatment of esophageal and gastroesophageal junction cancer: Accurate review of management and perspectives. *Crit Rev Oncol Hematol* 2018; **132**: 161-168 [PMID: 30447922 DOI: 10.1016/j.critrevonc.2018.10.002]

82 **Kawai M**, Yamaue H. [Evidence of Neoadjuvant Treatment for Pancreatic Cancer]. *Gan To Kagaku Ryoho* 2018; **45**: 1410-1414 [PMID: 30382034]

83 **Morandini AC**, Ramos-Junior ES, Potempa J, Nguyen KA, Oliveira AC, Bellio M, Ojcius DM, Scharfstein J, Coutinho-Silva R. Porphyromonas gingivalis fimbriae dampen P2X7-dependent interleukin-1β secretion. *J Innate Immun* 2014; **6**: 831-845 [PMID: 24925032 DOI: 10.1159/000363338]

84 **Yilmaz O**, Yao L, Maeda K, Rose TM, Lewis EL, Duman M, Lamont RJ, Ojcius DM. ATP scavenging by the intracellular pathogen Porphyromonas gingivalis inhibits P2X7-mediated host-cell apoptosis. *Cell Microbiol* 2008; **10**: 863-875 [PMID: 18005240 DOI: 10.1111/j.1462-5822.2007.01089.x]

85 **Lee J**, Roberts JS, Atanasova KR, Chowdhury N, Yilmaz Ö. A novel kinase function of a nucleoside-diphosphate-kinase homologue in Porphyromonas gingivalis is critical in subversion of host cell apoptosis by targeting heat-shock protein 27. *Cell Microbiol* 2018; **20**: e12825 [PMID: 29359393 DOI: 10.1111/cmi.12825]

86 **Yao L**, Jermanus C, Barbetta B, Choi C, Verbeke P, Ojcius DM, Yilmaz O. Porphyromonas gingivalis infection sequesters pro-apoptotic Bad through Akt in primary gingival epithelial cells. *Mol Oral Microbiol* 2010; **25**: 89-101 [PMID: 20331797 DOI: 10.1111/j.2041-1014.2010.00569.x]

87 **Yilmaz O**, Jungas T, Verbeke P, Ojcius DM. Activation of the phosphatidylinositol 3-kinase/Akt pathway contributes to survival of primary epithelial cells infected with the periodontal pathogen Porphyromonas gingivalis. *Infect Immun* 2004; **72**: 3743-3751 [PMID: 15213114 DOI: 10.1128/IAI.72.7.3743-3751.2004]

88 **Moffatt CE**, Lamont RJ. Porphyromonas gingivalis induction of microRNA-203 expression controls suppressor of cytokine signaling 3 in gingival epithelial cells. *Infect Immun* 2011; **79**: 2632-2637 [PMID: 21536793 DOI: 10.1128/IAI.00082-11]

89 **Sasaki A**, Yasukawa H, Suzuki A, Kamizono S, Syoda T, Kinjyo I, Sasaki M, Johnston JA, Yoshimura A. Cytokine-inducible SH2 protein-3 (CIS3/SOCS3) inhibits Janus tyrosine kinase by binding through the N-terminal kinase inhibitory region as well as SH2 domain. *Genes Cells* 1999; **4**: 339-351 [PMID: 10421843 DOI: 10.1046/j.1365-2443.1999.00263.x]

90 **Dong H**, Zhu G, Tamada K, Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. *Nat Med* 1999; **5**: 1365-1369 [PMID: 10581077 DOI: 10.1038/70932]

91 **Freeman GJ**, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne MC, Horton HF, Fouser L, Carter L, Ling V, Bowman MR, Carreno BM, Collins M, Wood CR, Honjo T. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. *J Exp Med* 2000; **192**: 1027-1034 [PMID: 11015443 DOI: 10.1084/jem.192.7.1027]

92 **Groeger S**, Domann E, Gonzales JR, Chakraborty T, Meyle J. B7-H1 and B7-DC receptors of oral squamous carcinoma cells are upregulated by Porphyromonas gingivalis. *Immunobiology* 2011; **216**: 1302-1310 [PMID: 21723642 DOI: 10.1016/j.imbio.2011.05.005]

93 **Dong H**, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, Lennon VA, Celis E, Chen L. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. *Nat Med* 2002; **8**: 793-800 [PMID: 12091876 DOI: 10.1038/nm730]

94 **Han YW**, Wang X. Mobile microbiome: oral bacteria in extra-oral infections and inflammation. *J Dent Res* 2013; **92**: 485-491 [PMID: 23625375 DOI: 10.1177/0022034513487559]

95 **Alevizos I**, Mahadevappa M, Zhang X, Ohyama H, Kohno Y, Posner M, Gallagher GT, Varvares M, Cohen D, Kim D, Kent R, Donoff RB, Todd R, Yung CM, Warrington JA, Wong DT. Oral cancer in vivo gene expression profiling assisted by laser capture microdissection and microarray analysis. *Oncogene* 2001; **20**: 6196-6204 [PMID: 11593428 DOI: 10.1038/sj.onc.1204685]

**P-Reviewer:** Chen YK, Sridharan G, Vynios D **S-Editor:** Ji FF **L-Editor: E-Editor:**

**Specialty type:** Medicine, research and experimental

**Country of origin:** China

**Peer-review report classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): C, C

Grade D (Fair): 0

Grade E (Poor): 0

****

**Figure 1 Possible mechanisms of cancers caused by *Porphyromonas gingivalis*.** When *Porphyromonas gingivalis* (*P. gingivalis*) infects the host, the expression of the B7-H1 receptor is activated, contributing to anergy and apoptosis of activated T cells, which eventually leads to immune evasion. Nucleoside diphosphate kinas (NDK) from *P. gingivalis* antagonizes ATP activation of purinergic receptor (P2X7) receptors and thus reduces the production of interleukin-1β and promotes tumourigenesis. NDK also phosphorylates heat shock protein 27 (HSP27); the phosphorylation of HSP27 and ATP activation of P2X7 receptor both inhibit apoptosis. The upregulation of miRNA-203 leads to inhibition of the negative regulator suppressor of cytokine signaling-3 (SOCS3), and SOCS3 can play a role of inhibiting JAK/STAT3 signalling, while the activation of Jak1/Akt/Stat3 signalling pathways and the increased Bcl2: Bax ratio induced by *P. gingivalis* infection both curtail the release of cytochrome c and block the activation of caspase-9 and caspase-3 that positively correlate with apoptosis. By activating the ERK1/2-Ets1, p38/HSP27, and PAR2/NF-kB signalling pathways, *P. gingivalis* induces the expression of proMMP-9, and the levels of MMPs also substantially increase after *P. gingivalis* infection; both consequently promote the invasion of tumour cells. *P. gingivalis* causes the host to be in a chronic inflammatory state. Inflammatory factors, such as IL-6 and IL-8, are subsequently released; the former causes DNA hypomethylation and tumourigenesis, and the latter inhibits the levels of MMPs and makes connections with the invasion of tumour cells. Additionally, the metabolism of carcinogenic substances and the activation of TRL are involved in tumourigenesis as well. NDK: Nucleoside diphosphate kinase; P2X7: Purinergic receptor; IL-1β: Interleukin-1β; HSP27: Heat shock protein 27; miR-203: miRNA-203; SOCS3: Suppressor of cytokine signaling-3; Jak1: Janus kinase 1; Stat3: Signal transducer and activator of transcription-3; Akt: Protein kinase B; Jak1/Stat3/Akt: Jak1/Stat3/Akt pathway; ERK1/2: Extracellular signal‐regulated kinase 1 and 2; Ets1: Ever shorter telomere 1; PAR2: Protease-activated receptor 2; NF-kB: Nuclear factor-kappa B; proMMP-9: Pro-matrix metalloproteinase-9; MMPs: Matrix metalloproteinase; IL-8/IL-6: Interleukin 8/interleukin 6; TLR: Toll-like receptor; BCL-2: B cell CLL/lymphoma-2.